At week 24, mean body weight reduction at the 12 mg amount was approximately 16.9%, with concentration-dependent reductions in HbA 1c across all retatrutide arms compared with placebo and dulaglutide
When drugs go into shortage, the US Food and Drug Administration allows compounding pharmacies to sell copycat versions to help fill in the gaps
Determining Candidacy for Treatment Adults with a BMI of 30 or more, or 27 with conditions like high blood pressure, cholesterol, or sleep apnea, are good candidates for weight loss treatments
Weight loss and physical activity changes: Patients achieving significant weight loss with GLP-1 therapy may experience changes in exercise tolerance and breathing patterns
Stopping retatrutide will not immediately stop shedding (the telogen transition already happened) and may lead to weight regain that creates additional metabolic stress
Pharmacies not registered with PCAB (Pharmacy Compounding Accreditation Board) or licensed by your state are not legitimate